Draft guideline on the clinical investigation of medicinal products in the treatment of patients with acute respiratory distress syndrome - Revision 2

Draft guideline on the clinical investigation of medicinal products in the treatment of patients with acute respiratory distress syndrome - Revision 2

Guidance on the details of the classification of variations requiring assessment according to Article 62 of Regulation (EU) 2019/6 for veterinary medicinal products and on the documentation to be submitted pursuant to those variations

Guidance on the details of the classification of variations requiring assessment according to Article 62 of Regulation (EU) 2019/6 for veterinary medicinal products and on the documentation to be submitted pursuant to those variations

Human medicines European public assessment report (EPAR): Somavert, pegvisomant, Date of authorisation: 12/11/2002, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Somavert, pegvisomant, Date of authorisation: 12/11/2002, Revision: 29, Status: Authorised

Joint EC/HMA/EMA multi-stakeholder workshop on pharmacogenomics, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 24 September 2024, 09:00 (CEST) to 24 September 2024, 17:00 (CEST)

Joint EC/HMA/EMA multi-stakeholder workshop on pharmacogenomics, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 24 September 2024, 09:00 (CEST) to 24 September 2024, 17:00 (CEST)

Human medicines European public assessment report (EPAR): GeGant, Germanium (68Ge) chloride,Gallium (68Ga) chloride, Status: Application withdrawn

Human medicines European public assessment report (EPAR): GeGant, Germanium (68Ge) chloride,Gallium (68Ga) chloride, Status: Application withdrawn

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness